Development of a novel drug treatment for decompensated heart failure
Ended Project Grant Awarded Last action
- Award ID
- R44HL131086
- Recipient
-
Madeleine Pharmaceuticals Inc. UEI NNNDGQCK6RV9
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,015,939
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $4,971,929.00 Federal
- $1,044,010.00 Non-federal
- Place of performance
- Wisconsin, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1 | $0 | |
| Amendment | $1 | $0 | |
| Amendment | $1,044,010 | $0 | |
| Amendment | $1,044,010 | $1,044,010 | |
| Amendment | $887,140 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $1,996,767 | $0 |
Quick answers
Who received award R44HL131086?
R44HL131086 was awarded to Madeleine Pharmaceuticals Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on May 1, 2016.
How much is award R44HL131086 worth?
$6,015,939 has been obligated on R44HL131086: $4,971,929 in federal funding and $1,044,010 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award